Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?

Emma Louise Robinson, Maral Azodi, Stephane Heymans, Ward Heggermont*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review


In the last decade, cardio-oncology has become a discipline on its own, with tremendous research going on to unravel the mechanisms underpinning different manifestations of cardiotoxicity caused by anticancer drugs. Although this domain is much broader than the effect of chemotherapy alone, a lot of questions about anthracycline-induced cardiotoxicity remain unknown. In this invited review, we provide insights in molecular mechanisms behind anthracycline-induced cardiotoxicity and put it in a clinical framework emphasizing the need for patients to understand, detect, and treat this detrimental condition.

Original languageEnglish
Pages (from-to)357-364
Number of pages8
JournalCurrent Heart Failure Reports
Issue number6
Publication statusPublished - Dec 2020

Cite this